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Background:  It is not  clear yet  how  tadalaﬁl  affects  nonischemic  cardiomyopathy,  although  its beneﬁcial
effects  on acute  myocardial  infarction  are  well-known.  We  investigated  tadalaﬁl’s  beneﬁcial  effects  on
nonischemic  cardiomyopathy  and  the  speciﬁc  mechanisms  of  its effects.
Methods: Cardiomyopathy  was  induced  in  mice  by  a single  intraperitoneal  injection  of  doxorubicin
(15  mg/kg).  In some  cases,  tadalaﬁl  (4 mg/kg/day,  p.o.,  14  days)  was  started  simultaneously.  After  two
weeks,  cardiac  function  was  evaluated  by  echocardiography  and  cardiac  catheterization,  then  all of  the
mice  were  killed  and  cardiac  specimens  were  subjected  for hemotoxylin  and  eosin  staining,  Masson’s
trichrome  staining,  terminal  deoxynucleotidyltransferase  dUTP  nick-end  labeling  assay,  enzyme-linked
immunosorbent  assay,  and Western  blot.
Results: Two  weeks  later,  left  ventricular  dilatation  and  dysfunction  were  apparent  in  mice  given doxoru-
bicin  but  were  signiﬁcantly  attenuated  by  tadalaﬁl  treatment.  Tadalaﬁl  also  protected  hearts  against
doxorubicin-induced  cardiomyocyte  atrophy/degeneration  and  myocardial  ﬁbrosis.  No  doxorubicin-
induced  apoptotic  effects  were  seen  between  groups.  Cardiac  cGMP  level  was lower  in  the
doxorubicin-treated  group,  however  it was  signiﬁcantly  increased  with  tadalaﬁl  treatment.  Compared  to
the  control  group,  the  myocardial  expression  of  3  sarcomeric  proteins,  myosin  heavy  chain,  troponin  I,
and  desmin  were  signiﬁcantly  decreased  in  the  doxorubicin-treated  group,  which  were  restored  by the
tadalaﬁl  treatment.
Conclusions:  The  present  study  indicates  a protective  effect  of  tadalaﬁl  mainly  through  cGMP  signaling
icin-
3  Jappathway  against  doxorub
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The antineoplastic drug doxorubicin (DOX) is widely used in
he therapy of various malignant tumors including leukemia, lym-
homas, and solid tumors such as ovarian, breast, lung, cervical,
nd uterine cancers [1]. However, its clinical use is limited by
ts adverse side effects: irreversible degenerative cardiomyopa-
hy and congestive heart failure [2,3]. The DOX-induced acute
ardiotoxicity is characterized by hypotension, arrhythmia, and
achycardia while the chronic effects are manifested as cardiac
ysfunction eventually leading to congestive heart failure [4,5].
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The development of cumulative dose-dependent cardiomyopathy
may occur many years after the cessation of DOX treatment [6,7].
Despite various therapeutic interventions adopted to protect the
heart against DOX-induced cardiotoxicity, the deterioration in
cardiac functions is often accompanied by high mortality rates.
So far, the ability of these treatments to protect the heart from
DOX-induced damage has been limited. Hence, there is an ongoing
need to further investigate and develop efﬁcient therapeutic
agents to combat DOX-induced cardiac damage.
Tadalaﬁl (Tad) is a potent long-acting selective inhibitor of
cGMP-speciﬁc phosphodiesterase-5 (PDE5), which hydrolyzes and
eliminates cGMP in cells [8]. A previous study has shown that the
long-acting PDE5 inhibitor, Tad, induces sustained cardioprotection
against lethal ischemic injury [9]. Several studies suggest that PDE5
inhibitors induce powerful beneﬁcial effects for pulmonary arterial
hypertension and ischemia/reperfusion injury [10,11]. Our most
recent study suggests that prolonged inhibition of PDE5 through
short hairpin RNA interference would relieve cardiac remodeling
vier Ltd. All rights reserved.
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sure and decreased LV ejection fraction and ±dP/dt, compared with
sham animals. Treatment with Tad signiﬁcantly mitigated the DOX-
induced impairment of cardiac function. Administration of Tad to
sham animals had no effect on cardiac function.
Table 1
Heart-to-body weight ratios among the groups.
Groups n Heart weights
(g)
Body weights
(g)
Heart-to-body
weight ratios (%)
Con 10 0.098 ± 0.08 26.42 ± 0.91 0.37 ± 0.019
*Z. Jin et al. / Journal of C
nd dysfunction following myocardial infarction [12]. There has
een only one study reporting beneﬁts of Tad on nonischemic
ardiomyopathy [13], thus little is known on the mechanisms
or Tad to exert such effects. It would be worth conﬁrming the
eneﬁcial effects of Tad on DOX-induced cardiomyopathy. In the
resent study, we examined the effects of Tad on DOX-induced
ardiomyopathy and investigated the speciﬁc mechanisms of its
ffects.
aterials and methods
This  study was approved by our Institutional Animal Research
ommittee and conformed to the animal care guidelines of the
merican Physiological Society. Cardiomyopathy was induced
n male 10-week-old C57BL/6J mice (Dalian Medical University,
alian, China) by a single intraperitoneal injection of DOX (Sigma,
t. Louis, MO,  USA) at a dose of 15 mg/kg, which has been reported
o be cardiotoxic [14]. The presence of DOX-induced cardiomyopa-
hy was conﬁrmed both functionally and histologically in all mice
hat were given no therapeutic intervention by the observation of
ecreased left ventricular (LV) function (by echocardiography and
ardiac catheterization). In sham-treated mice, the same volume
f saline was injected in a similar manner. Tad (Lilly, Indianapolis,
N, USA) tablets were crushed in water and given to animals orally
ia gauge needle at a dose of 4 mg/kg/day for successive 14 days.
his dose was chosen based on the interspecies dose extrapolation
caling to result in plasma concentrations equivalent to a human
ose of 20 mg/day [15]. Untreated control groups were given the
ame volume of saline.
Mice  were randomly assigned to receive (a) saline alone (Con
roup, n = 10); (b) DOX alone (DOX group, n = 16); (c) DOX plus Tad
DOX + Tad group, n = 16), or (d) Tad alone (Tad group, n = 10). Two
eeks later, all surviving mice were killed with an overdose of pen-
obarbital after physiological examination. The hearts were excised
nd weighed, cardiac specimens were then subjected to histologi-
al, immunohistochemical, and molecular biological analyses.
hysiological studies
Animals  were anesthetized via intraperitoneal injection with
entobarbital. Echocardiograms were then recorded with an
chocardiographic system (Aloka) equipped with a 7.5-MHz
maging transducer as reported previously [16]. LV end-systolic
iameter (LVDs) and end-diastolic diameter (LVDd) were mea-
ured from at least three consecutive cardiac cycles. After cardiac
chocardiography, the right carotid artery was cannulated with
 micromanometer-tipped catheter (SPR 407; Millar Instruments,
ouston, TX, USA) and advanced into the aorta and then into the
V to record pressure and ±dP/dt.
istological analysis
After  the echocardiography, each heart was removed and cut
nto 2 transverse slices. One was ﬁxed in 10% buffered forma-
in and embedded in parafﬁn, after which 4-m-thick sections
ere stained with hematoxylin–eosin (HE) or Masson. Quantitative
ssessments, including cell size and ﬁbrotic area, were performed
ith a multipurpose color image processor (Image Pro Plus) with
0 randomly chosen high-power ﬁelds in each heart.nzyme-linked immunoassay
Levels  of cGMP in the myocardium were assayed with an
nzyme-linked immunosorbent assay (ELISA) (CycLex, Nagano,
apan). Three hearts from each group were used for this assay.ogy 62 (2013) 110–116 111
In situ nick end-labeling
Terminal  dUTP nick end-labeling (TUNEL) assays were per-
formed in sections with an ApopTag kit (Intergene, Purchase, NY,
USA) mainly according to the instructions of the supplier. Mouse
mammary tissue served as a positive control.
Western blotting
Lysates/proteins from heart tissues were used for Western blot
analysis. Proteins were separated and transferred to membranes
by standard protocols, after which they were probed with antibod-
ies against myosin heavy chain (MHC), troponin I (both from Santa
Cruz, Dallas, TX, USA), desmin (Sigma). Three to ﬁve hearts from
each group were subjected to the blotting. The blots were visual-
ized by means of chemiluminescence (ECL, Thermo, Rockford, IL,
USA), and the signals were quantiﬁed by densitometry. a-Tubulin
(analyzed with an antibody from Thermo) served as the loading
control.
Statistical analysis
Statistical analysis was performed by using software of SPSS17.0
(Cary, NC, USA). Values are shown as mean ± SEM. The signiﬁcance
of differences between groups was  evaluated with 1-way ANOVA
followed by the Newman–Keuls multiple comparison test. Values
of p < 0.05 were considered signiﬁcant.
Results
Survival  rates and heart-to-body weight ratios
Two  weeks later, we evaluated survival rates and heart-to-body
weight ratios. Three of DOX and two of DOX + Tad mice were dead,
no mouse was dead in the Con or Tad groups. Survival rates of
the group treated with DOX + Tad (87.5%) exhibited increasing ten-
dency compared with the DOX group (81.25%) during the 14-day
experimental protocol, although this change was insigniﬁcant. The
heart-to-body weight ratio was  signiﬁcantly increased in the DOX
group, which was reversed by Tad (Table 1).
Physiological studies
The  results of our physiological studies are summarized in
Fig. 1. Echocardiography and cardiac catheterization performed
2 weeks after DOX administration showed that mice receiving
DOX alone had signiﬁcant cardiac functional deterioration char-
acterized by enlargement of the LV cavity and signs of decreased
cardiac function, i.e. increased LV diameter and end-diastolic pres-DOX  13 0.089 ± 0.13 21.26 ± 1.15 0.42 ± 0.037
DOX + Tad 14 0.092 ± 0.13 25.33 ± 1.02 0.36 ± 0.046#
Tad 10 0.092 ± 0.11 26.69 ± 1.16 0.34 ± 0.038
* p < 0.05 versus Con group.
# p < 0.05 versus DOX group.
Con,  control; DOX, doxorubicin; Tad, tadalaﬁl.
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Fig. 1. Effects of tadalaﬁl (Tad) on left ventricular (LV) geometry and function assessed 2 weeks after doxorubicin (DOX) injection using echocardiography and cardiac
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watheterization. Con, control; LVDd, LV diastolic diameter; LVDs, LV systolic diam
ressure; HR, heart rate. Bars are means ± SEM; *p < 0.05 versus Con group; #p < 0.0
istological analysis
Examination of transverse sections of hearts stained with H&E
Fig. 2A) revealed that the transverse diameters of cardiomyocytes
rom the group receiving DOX alone were signiﬁcantly smaller
han in the sham group (13.78 ± 0.36 m versus 14.42 ± 0.46 m,
 < 0.05), and that Tad exerted a signiﬁcant protective effect against
OX-induced atrophy (transverse diameter 14.24 ± 0.39 m;
ig. 2B). We  then assessed cardiac ﬁbrosis using Masson’s trichrome
taining sections (Fig. 2A), we found that the amount of ﬁbrosis
as signiﬁcantly higher in the group receiving DOX alone thanEF, percent ejection fraction; LVSP, LV systolic pressure; LVEDP, LV end-diastolic
us DOX group.
in  the sham group (5.16 ± 0.36% versus 1.39 ± 0.22%, p < 0.05) and
that the DOX-induced ﬁbrosis was signiﬁcantly reduced by Tad
(2.35 ± 0.21%; Fig. 2B).
TUNEL-positive cells
TUNEL-positive cells were observed among cardiomyocytes
from all 4 groups, but we  found no signiﬁcant difference in the
incidence of TUNEL-positive cells between mice that received DOX
and those that did not, and Tad had no signiﬁcant effect on the
incidence of TUNEL-positive cells (Fig. 2C). These results indicate
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Fig. 2. Effects of Tad on cardiac histology in mice 2 weeks after DOX injection. (A) Photomicrographs of histological hematoxylin–eosin (HE) and Masson’s trichrome staining
of  heart specimens. (B) Graphs showing morphometric data. Bars are means ± SEM; *p < 0.05 versus Con group; #p < 0.05 versus DOX group. (C) Graphs show the terminal
d re me
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wUTP nick end-labeling assay-based apoptotic index among cardiomyocytes. Bars a
hat apoptosis is not involved in the present model of DOX-induced
ardiomyopathy.
ardiac cGMP level
Treatment  with DOX decreased cGMP levels in the heart com-
ared with the saline-treated control (Fig. 3A). The combined
reatment with Tad and DOX augmented cGMP levels compared
ith DOX alone.
xpression of sarcomeric proteinsWe found myocardial levels of 3 sarcomeric proteins, MHC, tro-
onin I, and desmin, were signiﬁcantly downregulated by DOX. The
nhibitory effect of DOX on the expression of all 3 of these proteins
as completely reversed by Tad (Fig. 3B and C).ans ± SEM; p = ns. Con, control; DOX, doxorubicin; Tad, tadalaﬁl.
Discussion
We used an oral administration regimen of Tad (4 mg/kg/day
for 14 days), which is similar to reported levels in human subjects
taking clinically relevant doses of Tad (20 mg p.o. daily for 1 week)
[15].
The present study provides the important evidence of the
beneﬁcial effects of Tad on cardiac dysfunction resulting from
DOX-induced cardiomyopathy, a nonischemic cardiomyopathy.
The prominent interesting ﬁndings were that Tad prevented DOX-
induced atrophic degeneration of cardiomyocytes and cardiac
ﬁbrosis. Our ﬁndings suggest that several factors contribute to the
cardioprotective effects of Tad against DOX-induced cardiomyopa-
thy. The ﬁrst is that Tad exerts an anti-atrophic/degenerative effect
on cardiomyocytes. Sarcomeric proteins, including MHC, troponin I,
and desmin, are important for the structural integrity and function
of cardiomyocytes, and their myocardial expression is reportedly
114 Z. Jin et al. / Journal of Cardiology 62 (2013) 110–116
Fig. 3. Enzyme-linked immunosorbent assay (ELISA) and Western analysis of the effects of Tad on myocardial expression of cGMP and three sarcomeric proteins: MHC,
troponin I, and desmin. (A) Levels of cGMP in the myocardium were assayed with an ELISA. Bars are means ± SEM; *p < 0.05 versus Con group; #p < 0.05 versus DOX  group.
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cB and C) Western blot analysis of effect of Tad on myocardial expression of 3 sarco
roup; #p < 0.05 versus DOX group. Con, control; DOX, doxorubicin; Tad, tadalaﬁl; M
ownregulated by DOX [17], an effect we conﬁrmed in the present
tudy. Our new ﬁnding is that Tad signiﬁcantly restores the expres-
ion of sarcomeric proteins in the presence of DOX.
In  the present study, we also observed that DOX stimulates
yocardial ﬁbrosis, which is consistent with the previous study
18] and that Tad prevents the pathological process. Because
yocardial ﬁbrosis contributes to both systolic and diastolic dys-
unction [5,19], its reduction is likely another important way in
hich Tad may  mitigate LV remodeling and heart failure.
The  exact pathogenesis of DOX-induced cardiotoxicity is still
ot entirely clear although a diverse set of mechanisms have been
roposed, including oxidative stress, mitochondrial DNA damage,
ntracellular calcium overload, cytokine release, cardiomyocyte
poptosis and cardiomyocyte atrophy [20–23,3,24]. A previous
nding indicates that apoptosis among cardiomyocytes is a leading
ause of cardiac dysfunction in DOX-induced cardiomyopathy [25].
eeking evidence of DOX-induced apoptosis, we conducted a series
f TUNEL assays but detected no effect of DOX or Tad on the inci-
ence of apoptosis. Thus, our ﬁndings suggest that cardiomyocyte
poptosis is not important for disease progression in the present
odel. It has been reported that cardiomyocyte atrophy plays a
ajor role in the DOX-induced cardiomyopathy [24]. In our experi-
ent, we conﬁrmed that DOX signiﬁcantly induced cardiomyocyte
trophy. Our important ﬁnding was that Tad signiﬁcantly atten-
ated DOX-induced cardiomyocyte atrophy. We  speculate that
ardiomyocyte atrophy is a main reason to cause DOX-induced proteins, MHC, troponin I, and desmin. Bars are means ± SEM; *p < 0.05 versus Con
yosin heavy chain.
impairment of cardiac function, and that Tad plays a protective role
by mitigating the DOX-induced cardiomyocyte atrophy.
cGMP  is an intracellular second messenger that mediates mul-
tiple tissue and cellular responses, including its role in late-phase
preconditioning [26,27]. cGMP plays important roles in the regu-
lation of smooth muscle relaxation, platelet aggregation, intestinal
secretion, and endochondrial ossiﬁcation through the activation of
cGMP-dependent protein kinase [28]. Under physiological condi-
tions, cGMP is inactivated via hydrolytic degradation by PDE. PDE5
negatively regulates intracellular cGMP level and its activity [29].
PDE5 inhibitors have been observed to play a critical role against
cardiac ischemia-reperfusion injuries by activating cGMP/cyclic
GMP-dependent protein kinase (PKG) signaling pathway [30]. The
PDE5A inhibitor, sildenaﬁl, can prevent myocyte hypertrophy, and
improve heart function of mice exposed to chronic pressure over-
load induced by transverse aortic constriction through blocking the
intrinsic catabolism of cGMP [31]. However, the role of cGMP/PKG
signaling in protection against DOX-induced cardiotoxicity is not
well-known yet.
A  previous study has found that cGMP can promote rat glial
cells and microglia MHC  expression [32]. It has been reported
that PDE5 inhibition prompted troponin I phosphorylation through
PKG-dependent cGMP signaling pathway [33]. In the present study,
we found that Tad signiﬁcantly restores, with accompaniment of
cGMP increase, the myocardial expression of MHC,  troponin I, and
desmin which were decreased in the DOX group. We  speculate
Z. Jin et al. / Journal of Cardiol
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Fig. 4. Proposed scheme showing possible mechanisms for the protective effects of
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[adalaﬁl against doxorubicin-induced nonischemic cardiomyopathy. PDE5, phos-
hodiesterase 5; PKG, cyclic GMP-dependent protein kinase; TGF, transforming
rowth  factor; MHC, myosin heavy chain; TnI, troponin I.
hat Tad upregulates the expression of myocardial MHC, troponin
, and desmin through activating cGMP signaling pathway, that
nally prevents cardiomyocyte atrophy and degeneration induced
y DOX. A previous study has found that myocardial ﬁbrosis asso-
iated with the increased expression of transforming growth factor
TGF)-1 and cGMP can reduce cardiac ﬁbrosis through inhibiting
xpression of TGF-1 [34]. In our study, we observed a signiﬁcant
ncrease in cGMP levels and decrease in ﬁbrosis in the hearts of
ice treated with DOX + Tad compared to DOX alone. Fibrosis is
onsidered to be a common pathological change of cardiac remod-
ling and heart failure; inhibition of myocardial ﬁbrosis leads to the
mprovement of cardiac function. The present study indicates that
ad reduces DOX-induced myocardial ﬁbrosis possibly through up-
egulation of cGMP concentration. We  therefore suggest that Tad
xerts its beneﬁcial effects via the cGMP signaling pathway (Fig. 4),
hich was otherwise inhibited in the DOX group.
onclusion
The present study suggests the protective effects of Tad
gainst DOX-induced cardiomyopathy, mitigating DOX-induced
mpairment of cardiac function in mice, signiﬁcantly attenuating
OX-induced atrophic degeneration of cardiomyocyte and myocar-
ial ﬁbrosis possibly through the cGMP signaling pathway.
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